Colon Cancer - Avastin Falls Short in Colon Cancer Trial - New York Times
Avastin Falls Short in Colon Cancer Trial - New York Times
The drug Avastin failed to prevent colon cancer from recurring by a significant amount in a clinical trial, the drug s manufacturer, Genentech, said early Wednesday. The results of the trial had been closely watched because a success would have
Cancer’s still a fight, not a death sentence - Caspar Star-Tribune
Kim Rogers can’t have another child to give her son a brother or a sister. Joe Luck questions if the disease has returned with every sniffle, ache or fever. Anita LaFleiche feels she still owes the medical community — and her community of Powell
More Utahns getting colon cancer screening - ABC 4
SALT LAKE CITY (ABC 4 News) - There is some good news about the second leading cancer killer in utah. In the last five years, Utah’s screening rate for colon cancer has gone up twenty-five percent. That means more people are getting colonoscopies
Avastin fails to hit colon cancer target - United Press International
SAN FRANCISCO, April 22 (UPI) — The drug Avastin fell short in a clinical trial of its goal to reduce the recurrence of early-stage colon cancer, U.S. drug maker Genentech says. The Phase III study, which looked at the effectiveness of chemotherapy